{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '11.7.', 'Appendix 7: Clinical Laboratory Tests', 'The tests detailed in Table 5 will be performed by central laboratory services,', 'with the exception of exceptional circumstances during screening noted in', 'Section 5. Please refer to Appendix 14 in Section 11.14 for study management', 'information during the COVID-19 pandemic.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 5 of the protocol.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Table 5', 'Protocol Required Safety Laboratory Assessments', 'Hematology:', 'Platelet count', 'Automated WBC differential:', 'RBC count', 'Neutrophils', 'WBC count (absolute)', 'Lymphocytes', 'Hemoglobin', 'Monocytes', 'Hematocrit', 'Eosinophils', 'MCV', 'Basophils', 'MCH', 'Clinical Chemistry:', 'Total bilirubina', 'BUN', 'Potassium', 'AST', 'Direct bilirubina', 'Creatinine', 'Chloride', 'ALT', 'Albumin', 'Glucoseb', 'Total CO2', 'Alkaline phosphatase', 'GFR/Creatinine clearance', 'Sodium', 'Phosphate', 'Cystatin-C (Day 1 only)', 'Calcium', 'Protein', 'Creatine Phosphokinase', 'Fasting Lipid Paneld', 'Total cholesterol', 'HDL cholesterol', 'LDL cholesterol', 'Triglycerides', 'Urinalysis', 'specific gravity, pH, glucose, protein, blood and ketones by dipstick (with microscopic examination if blood', 'or protein is abnormal), urine albumin/creatinine ratio, urine protein/creatinine ratio, urine phosphate', 'Other Tests', 'Plasma HIV-1 RNAe', 'CD4+ and CD8+ lymphocyte counts, CD4+/CD8+ cell count ratio', 'Hepatitis B (HBsAg, anti-HBc, anti-HBs, HBV DNA)', 'Hepatitis C (anti-HCV)', 'PT/INR', 'Pregnancy test for women of childbearing potential', 'Renal biomarkers including Cystatin-C (blood), Retinol Binding Protein (RBP, urine); and', 'Beta-2-Microglobulin (B2M, urine), urine RBP/creatinine ratio, urine B2M/creatinine ratiog', 'Bone biomarkers including: Bone-specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1', 'collagen cross-linked C-telopeptide, osteocalcin', 'Inflammation Biomarkers: Interleukin-6 (IL-6), High-sensitivity C reactive protein (hs-CRP), D-dimer, Soluble', 'CD14 (sCD14), Soluble CD163 (sCD163)', 'HbA1c and insulin and glucose for HOMA-IR calculation', '104']['2017N331008_06', 'CONFIDENTIAL', '208090', 'MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin, RBC = red blood cells, WBC = white blood', 'cells, BUN = Blood urea nitrogen, AST=aspartate aminotransferase, ALT = alanine aminotransferase, CO2 = carbon', 'dioxide, HDL = high density lipoprotein, LDL = low density lipoprotein, HbsAg= hepatitis B virus surface antigen,', 'PT/INR = prothrombin time/international normalized ratio, HbA1c = glycated haemoglobin, HOMA-IR = homeostasis', 'model of assessment - insulin resistance, IL-6 = interleukin-6, hs-CRP = high-sensitivity C reactive protein, sCD', '=', 'soluble CD.', 'a) Direct bilirubin will be reflexively performed for all total bilirubin values -1.5 x ULN.', 'b)', 'For fasting glucose assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast is', 'acceptable for participants with afternoon appointments.', 'c)', 'Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease', 'Epidemiology Collaboration (CKD-EPl-creatinine) [Levey, 2009]. In addition, GFR will be estimated by the central', 'laboratory using the CKD-EPI-cystatin C [Inker, 2012] at day 1 and when indicated by renal toxicity criteria.', 'd)', 'For fasting lipids assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast is acceptable', 'for participants with afternoon appointments.', 'e)', 'For participants meeting virologic withdrawal criteria, plasma samples will be analyzed in attempt to obtain', 'genotype/phenotype data.', 'f)', 'Urine pregnancy test/ serum pregnancy test will be performed according to the Schedule of Activities.', 'g)', 'The intention is to utilize these biomarker data for research purposes; the sponsor will not be reporting real-time', 'results of these assessments to the investigator, except for Cystatin C (Day 1 only) and HbA1c.', 'References', 'Levey AS, Stevens LA, Schmid CH, et.al. A new equation to estimate glomerular', 'filtration rate. Ann Int Med. 2009; 150:604-12.', '105']\n\n###\n\n", "completion": "END"}